Swiss National Bank Sells 16,100 Shares of Hologic, Inc. (NASDAQ:HOLX)

Key Points

• Swiss National Bank sold 16,100 shares of Hologic, Inc., reducing its stake by 2.5%, but still holds 640,140 shares valued at approximately $39.5 million.
• For the latest quarter, Hologic reported $1.08 EPS, exceeding analysts' expectations, along with a revenue increase of 1.2% year-over-year, totaling $1.02 billion.
• Equity analysts have a consensus rating of "Moderate Buy" for Hologic, with an average price target of $77.83 following several price target upgrades from various firms.

Swiss National Bank reduced its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 640,140 shares of the medical equipment provider's stock after selling 16,100 shares during the period. Swiss National Bank owned 0.29% of Hologic worth $39,541,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HOLX. Victory Capital Management Inc. lifted its position in shares of Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after acquiring an additional 1,692,177 shares in the last quarter. Champlain Investment Partners LLC acquired a new position in Hologic in the 4th quarter valued at approximately $79,291,000. Redwood Wealth Management Group LLC acquired a new position in Hologic in the 1st quarter valued at approximately $3,534,000. Northern Trust Corp increased its stake in Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares during the period. Finally, Sound Shore Management Inc. CT increased its stake in shares of Hologic by 42.6% during the 1st quarter. Sound Shore Management Inc. CT now owns 1,383,628 shares of the medical equipment provider's stock worth $85,467,000 after purchasing an additional 413,403 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HOLX has been the subject of several recent analyst reports. UBS Group upped their price objective on shares of Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and increased their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Ten analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.83.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded down $0.17 on Friday, hitting $67.90. The company had a trading volume of 627,242 shares, compared to its average volume of 2,787,181. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The stock has a market cap of $15.10 billion, a price-to-earnings ratio of 28.18, a P/E/G ratio of 2.50 and a beta of 0.49. The stock has a 50 day moving average price of $65.53 and a 200 day moving average price of $62.66. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the company posted $1.06 earnings per share. Hologic's revenue was up 1.2% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.